$DNTH

$79.33 +$2.55 (3.32%) Close

$DNTH Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 55.9M shares outstanding

Who owns DNTH?

By type of holder

Institutions 100.0% Insiders 0.0% Everyone else 0.0%

Concentration Top 10 holders own 59.5%

FMR LLC 14.7% · Avidity Partners Management LP 3.8%

Institutional ownership

100.0%

0 pts vs last qtr

Institutional holders

266

+25 vs last qtr

Net shares bought

+1.4M

by institutions in Q2 2026

New / sold out

63 / 38

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

T. Rowe Price Investment Management, Inc. +2.6M
Price T Rowe Associates Inc /MD/ +1.4M

Biggest sellers in Q2 2026

Ra Capital Management, L.P. SOLD OUT −2.6M
Avidity Partners Management LP −2.1M

Who is planning to sell?

Notices of proposed sale, last 12 months

$47.7M

13 notices from 6 people

Shares covered

676.1K

1.21% of the company

Arranged in advance

100%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Ryan Savitz Officer 10b5-1 $13.7M
Simrat Randhawa Officer 10b5-1 $13M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2020–FY2025

+5527.3%

+123.90% a year

Each share's claim on the business

−98.2%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $50.1M

over 6 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years67% Under 1 year33%

Quarterly turnover

20.3%

of institutional shares changed hands

Top 10 managers, median time held

2.8 years

Super Investors

Investment managers reporting DNTH on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
F FMR LLC	8.2M	14.66%	+432.2K (+5.6%)	2023	0.0%
Shares held by quarter Peak holding8.2M (Q2'26) Change over 8 quarters+3.8M Share of the company14.660% FMR LLC's full portfolio →
AP Avidity Partners Management LP 13D · 4.9%	2.1M	3.76%	−2.1M (−50.0%)	2023	32.9%
Shares held by quarter Peak holding4.2M (Q1'26) Change over 8 quarters−813.0K Share of the company3.760% Disclosed stake13D · 4.9% Avidity Partners Management LP's full portfolio →

FMR LLC

8.2M

% of company

14.66%

Change vs last qtr

+432.2K (+5.6%)

Held since

2023

Avidity Partners Management LP

13D · 4.9%

2.1M

% of company

3.76%

Change vs last qtr

−2.1M (−50.0%)

Held since

2023

28 more super investors behind a free account

See every manager holding Dianthus Therapeutics, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting DNTH on Form N-PORT; together they hold 46.6% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
FG Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust	$168M	1.6M	2.85%	0.17%	August 31, 2026
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$161M	1.6M	2.95%	0.01%	June 30, 2026

Fidelity Growth Company Fund

Fidelity Mt. Vernon Street Trust

Position value

$168M

% of company

2.85%

% of the fund

0.17%

As of

August 31, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$161M

% of company

2.95%

% of the fund

0.01%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Dianthus Therapeutics, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
TK Tomas Kiselak 5%+ holder 13D · 4.9%	2.1M	3.83%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company3.830% Disclosed stake13D · 4.9% View the 13D/G filing →
PE Peter Evan Harwin 5%+ holder 13D · 4.9%	2.1M	3.83%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company3.830% Disclosed stake13D · 4.9% View the 13D/G filing →

Tomas Kiselak

5%+ holder13D · 4.9%

2.1M

% of company

3.83%

Change vs last qtr

—

Held since

—

Peter Evan Harwin

5%+ holder13D · 4.9%

2.1M

% of company

3.83%

Change vs last qtr

—

Held since

—

4 more holders behind a free account

See every insider and 5%+ holder of Dianthus Therapeutics, Inc..

Comments